Lonza Group refines biologics strategy, shares anchored in the SMI healthcare cohort
24.06.2026 - 08:46:20 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-24, 08:45.
Lonza Group (CH0013841017) operates as a key contract development and manufacturing organization for pharma and biotech customers in Switzerland. The stock is part of the Swiss Market Index and sits in the healthcare cohort alongside peers Roche and Novartis.
Contract manufacturing in focus
Lonza Group has oriented its business strongly toward biologics manufacturing and contract services over recent years, positioning as a leading CDMO for monoclonal antibodies and other complex biologics. The company’s Swiss plants supply global pharmaceuticals with development and manufacturing capacity across multiple therapeutic areas.
Within the SMI, Lonza Group is grouped in the healthcare sector, where large-cap peers such as Roche and Novartis set benchmarks for margins and innovation intensity. Investors often compare Lonza Group’s growth and margin profile to these names when assessing operational strategy in the Swiss healthcare cluster.
Operational strategy and global footprint
Lonza Group’s operating model combines biologics manufacturing with small molecules and specialty ingredients, with major sites in Visp and Basel serving as strategic hubs. Capacity expansions in biologics and cell therapy underscore the company’s focus on higher-value CDMO contracts and long-term customer relationships.
The company’s global footprint extends beyond Switzerland, with manufacturing and service locations in Europe, North America and Asia supporting worldwide pharmaceutical supply chains. This geographic spread allows Lonza Group to serve multinational customers and diversify operational risks across regions and product lines.
More news and data on the Lonza Group shares
Background reports, trading data and further company disclosures help investors track Lonza Group in the Swiss healthcare segment.
What the company sells
Lonza Group generates revenue mainly from contract development and manufacturing services for biologics, including monoclonal antibodies, cell therapies and viral vectors. The company also offers development and production capabilities for small molecules and specialty ingredients used in pharmaceutical and nutritional applications.
Where the stock trades today
The Lonza Group shares (CH0013841017) trade on the SIX Swiss Exchange, where they are part of the Swiss Market Index in the healthcare segment. Recent trading shows the stock priced in Swiss francs in line with other large-cap Swiss healthcare names.
Key data on the Lonza Group shares
- Company: Lonza Group AG
- ISIN: CH0013841017
- WKN: 1013786
- Ticker: LONN
- Trading venue: SIX Swiss Exchange
- Price (as of 2026-06-24, 08:45): 0.00 CHF
- Market cap: 0.00 CHF (as of 2026-06-24)
- Sector / industry: Health Care, Pharmaceuticals & Biotechnology, Contract Development and Manufacturing
- Index membership: SMI
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer or solicitation to buy or sell any securities. All data are based on sources deemed reliable but may be subject to change.
